Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)

238.07
Delayed Data
As of 3:22pm ET
 +6.64 / +2.87%
Today’s Change
117.58
Today|||52-Week Range
239.68
+40.39%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$28.8B

Company Description

Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Contact Information

Alnylam Pharmaceuticals, Inc.
675 West Kendall Street
Cambridge Massachusetts 02142
P:(617) 551-8200
Investor Relations:
(617) 551-8276

Employees

Shareholders

Mutual fund holders67.90%
Other institutional41.44%
Individual stakeholders18.09%

Top Executives

Yvonne L. GreenstreetChief Executive Officer & Director
Akshay K. VaishnawPresident
Jeffrey V. PoultonChief Financial Officer & Executive Vice President
Pushkal P. GargChief Medical Officer & EVP-Medical Affairs
James P. BilottaChief Information Officer & SVP